High molecular weight kininogen is an inhibitor of platelet calpain

• Published in: The Journal of clinical investigation 1986-05, Vol.77 (5), p.1565-1573
• Main Authors: SCHMAIER, A. H, BRADFORD, H, SILVER, L. D, FARBER, A, SCOTT, C. F, SCHUTSKY, D, COLMAN, R. W
• Format: Article
• Language: English
• Subjects: alpha-Macroglobulins - pharmacology; Biological and medical sciences; Blood coagulation. Blood cells; Blood Physiological Phenomena; Blood Platelets - enzymology; Blood Proteins - pharmacology; Calcium - physiology; Calpain - isolation & purification; Fundamental and applied biological sciences. Psychology; Glycoproteins; Humans; Iodine Radioisotopes; Kinetics; Kininogens - metabolism; Kininogens - pharmacology; Molecular and cellular biology; Molecular Weight; Platelet
• ISSN: 0021-9738; 1558-8238
• DOI: 10.1172/jci112472

Recent studies from our laboratory indicate that a high concentration of platelet-derived calcium-activated cysteine protease (calpain) can cleave high molecular weight kininogen (HMWK). On immunodiffusion and immunoblot, antiserum directed to the heavy chain of HMWK showed immunochemical identity with alpha-cysteine protease inhibitor--a major plasma inhibitor of tissue calpains. Studies were then initiated to determine whether purified or plasma HMWK was also an inhibitor of platelet calpain. Purified alpha-cysteine protease inhibitor, alpha-2-macroglobulin, as well as purified heavy chain of HMWK or HMWK itself inhibited purified platelet calpain. Kinetic analysis revealed that HMWK inhibited platelet calpain noncompetitively (Ki approximately equal to 5 nM). Incubation of platelet calpain with HMWK, alpha-2-macroglobulin, purified heavy chain of HMWK, or purified alpha-cysteine protease inhibitor under similar conditions resulted in an IC50 of 36, 500, 700, and 1,700 nM, respectively. The contribution of these proteins in plasma towards the inhibition of platelet calpain was investigated next. Normal plasma contained a protein that conferred a five to sixfold greater IC50 of purified platelet calpain than plasma deficient in either HMWK or total kininogen. Reconstitution of total kininogen deficient plasma with purified HMWK to normal levels (0.67 microM) completely corrected the subnormal inhibitory activity. However, reconstitution of HMWK deficient plasma to normal levels of low molecular weight kininogen (2.4 microM) did not fully correct the subnormal calpain inhibitory capacity of this plasma. These studies indicate that HMWK is a potent inhibitor as well as a substrate of platelet calpain and that the plasma and cellular kininogens may function as regulators of cytosolic, calcium-activated cysteine proteases.